#1 Clinical Trials Search in Europe

Terlipressin Acetate

Terlipressin Acetate is a drug being studied in clinical trials for its potential benefits in treating cirrhosis, portal hypertension, and related complications such as refractory ascites. These trials aim to evaluate the safety, efficacy, and hemodynamic effects of Terlipressin when administered through different methods, including continuous infusion and bolus injection. The research focuses on how this medication impacts various aspects of liver and kidney function in patients with these conditions.

Table of Contents

What is Terlipressin Acetate?

Terlipressin acetate, also known simply as terlipressin, is a medication used in the treatment of certain liver-related conditions[1]. It belongs to a class of drugs called vasopressin analogues, which means it works similarly to a hormone naturally produced in the body called vasopressin. This hormone helps regulate blood pressure and water retention in the body.

Medical Conditions Treated with Terlipressin

Terlipressin is primarily used to treat complications associated with liver diseases. The main conditions it’s used for include:

  • Cirrhosis with refractory ascites: Cirrhosis is a condition where the liver becomes scarred and damaged. Refractory ascites is a complication of cirrhosis where fluid builds up in the abdomen and doesn’t respond well to standard treatments[1].
  • Portal hypertension: This is high blood pressure in the portal vein, which carries blood from the digestive organs to the liver. It’s often a complication of cirrhosis[2].

How is Terlipressin Administered?

Terlipressin can be administered in different ways, depending on the specific treatment plan and clinical trial:

  1. Continuous infusion: In some cases, terlipressin is given as a continuous infusion using an ambulatory pump. This means the medication is slowly and steadily delivered into your bloodstream over an extended period, typically several days or weeks[1].
  2. Intravenous (IV) bolus injection: In other cases, terlipressin may be given as a single dose injected directly into a vein[2].

Current Clinical Trials and Research

Terlipressin is currently being studied in various clinical trials to better understand its effects and potential uses. Some of the ongoing research includes:

  • A study on low-dose continuous infusion of terlipressin in patients with cirrhosis and refractory ascites. This trial aims to determine if terlipressin can help manage ascites and reduce the need for procedures to remove excess fluid from the abdomen[1].
  • An exploratory study investigating the effects of terlipressin on blood flow in various organs, including the liver and kidneys, in patients with compensated cirrhosis and portal hypertension[2].

Effects of Terlipressin on the Body

Terlipressin works by affecting blood flow in various parts of the body. Some of its effects include:

  • Reducing portal pressure: Terlipressin can help lower the pressure in the portal vein, which may help manage complications of portal hypertension[2].
  • Affecting renal (kidney) blood flow: Research is being conducted to understand how terlipressin impacts blood flow to the kidneys[2].
  • Impacting hepatic (liver) blood flow: Studies are also looking at how terlipressin affects blood flow in the liver[2].
  • Managing ascites: Terlipressin may help reduce the accumulation of fluid in the abdomen (ascites) and decrease the need for procedures to remove this fluid[1].

Safety and Side Effects

As with any medication, terlipressin can have side effects. The safety of terlipressin is closely monitored in clinical trials. Some studies are specifically designed to assess the safety and tolerability of the drug[2]. Potential side effects and safety concerns are typically evaluated through:

  • Physical examinations
  • Laboratory safety tests
  • Monitoring for adverse events

It’s important to note that the full range of potential side effects may not be known, especially for new uses or administration methods being studied in clinical trials. Always discuss potential risks and benefits with your healthcare provider.

Aspect Details
Drug Name Terlipressin Acetate
Conditions Studied Cirrhosis, Portal Hypertension, Refractory Ascites
Administration Methods Continuous infusion, Intravenous bolus injection
Primary Outcomes Measured Safety, Efficacy, Blood flow changes, Portal pressure changes
Secondary Outcomes Changes in paracentesis requirements, Blood flow in various organs
Study Designs Open-label prospective study, Exploratory hemodynamic study
Comparison Drug Serelaxin (RLX030) in one study
Treatment Duration Varies from acute responses (hours) to extended treatment (28 days)

FAQ

  • What is Terlipressin Acetate used for in these clinical trials? Terlipressin Acetate is being studied for its potential benefits in treating cirrhosis, portal hypertension, and related complications such as refractory ascites. It is being evaluated for its effects on liver and kidney function in patients with these conditions.
  • How is Terlipressin Acetate administered in these trials? In the trials, Terlipressin Acetate is administered through different methods, including continuous infusion via an ambulatory pump and as an intravenous (IV) bolus injection. The specific method and dosage may vary depending on the study.
  • What are some of the outcomes being measured in these trials? The trials are measuring various outcomes, including the safety and tolerability of Terlipressin, its effects on blood flow in different organs (such as the kidneys and liver), changes in portal pressure, and its impact on the need for procedures like large volume paracentesis in patients with refractory ascites.
  • How long do the treatments typically last in these trials? The duration of treatment varies between trials. For example, one study involves a 28-day treatment period with Terlipressin continuous infusion, while another study measures acute responses over a few hours.
  • Are there any other drugs being compared to Terlipressin Acetate in these trials? In one of the trials, Terlipressin Acetate is being compared to another drug called Serelaxin (RLX030). Both drugs are being evaluated for their effects on patients with compensated cirrhosis and portal hypertension.

Ongoing Clinical Trials on Terlipressin Acetate

  • Study on Noradrenaline and Terlipressin for Treating Septic Shock in Patients

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Safety and Effectiveness of R2R01 and Terlipressin for Patients with Hepatorenal Syndrome and Acute Kidney Injury

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy

Glossary

  • Cirrhosis: A late stage of scarring (fibrosis) of the liver caused by many forms of liver diseases and conditions. In cirrhosis, the liver is scarred and permanently damaged, which can lead to serious complications.
  • Portal Hypertension: Increased blood pressure in the portal venous system, which includes veins that carry blood from the intestines to the liver. It's often a result of cirrhosis and can lead to various complications.
  • Refractory Ascites: A condition where fluid accumulates in the abdominal cavity and doesn't respond well to standard treatments like diuretics. It's a common complication of advanced liver disease.
  • Paracentesis: A procedure where a needle or catheter is inserted into the abdominal cavity to remove excess fluid (ascites). It's often used to relieve symptoms or for diagnostic purposes.
  • Pharmacokinetic: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion. It helps determine the appropriate dosing and timing of medication.
  • Steady State Concentration: The point at which the amount of drug entering the body is equal to the amount being eliminated, resulting in a constant concentration in the blood.
  • Hemodynamic: Relating to the flow of blood within the organs and tissues of the body. Hemodynamic measurements can provide important information about how drugs affect blood circulation.
  • Magnetic Resonance Angiography (MRA): A type of magnetic resonance imaging (MRI) scan that specifically looks at blood vessels and blood flow in various parts of the body.
  • Transjugular Intrahepatic Portosystemic Shunt (TIPSS): A procedure that creates a new route for blood to flow within the liver, bypassing the damaged liver tissue. It's often used to treat complications of portal hypertension.
  • Portal Pressure Gradient (PPG): The difference in pressure between the portal vein (which carries blood to the liver) and the hepatic vein (which carries blood away from the liver). It's an important measure in assessing portal hypertension.

References

  1. https://clinicaltrials.gov/study/NCT03107091
  2. https://clinicaltrials.gov/study/NCT01640964